Top

Published in:

Open Access 01-10-2016 | Original Investigation

Highly individual patterns of virus-immune IgG effector responses in humans

Authors: Eugenia Corrales-Aguilar, Mirko Trilling, Henrike Reinhard, Valeria Falcone, Albert Zimmermann, Ortwin Adams, Sabine Santibanez, Hartmut Hengel

Published in: Medical Microbiology and Immunology | Issue 5/2016

Abstract

IgG responses are fundamental to adaptive immunity and document immunological memory of previous pathogen encounter. While specific antigen recognition is mediated by the variable F(ab′)₂ domain of IgG, various effector functions become activated via the constant Fcγ part bridging IgG-opsonized targets to FcγR-expressing immune effector cells. Traditionally, neutralizing IgG is considered the most appropriate correlate of protective humoral immunity to viruses. However, evidence is increasing that antiviral IgG mediates protection to viruses via activation of FcγRs. Using a test system allowing quantitative detection of virus-immune IgG able to activate FcγRs, sera of healthy individuals and vaccinees were assessed with regard to two prototypical human pathogenic viruses: measles and human cytomegalovirus. Marked differences in the capacity of individuals to generate FcγRI-, FcγRII- and FcγRIII-activating responses were noted. Comparison of FcγR-activating IgG with neutralizing and ELISA IgG concentrations did not correlate for HCMV and only very poorly for MV. Since neither neutralizing IgG nor overall IgG responses faithfully predict the activation of FcγRs, only the simultaneous quantification of IgGs activating defined FcγRs will aid to delineate individual “immunograms” of virus IgG immunity. Such new multiparametric assessment of antiviral IgG qualities could be instrumental in defining correlates of protection and disease progression.

Available only for authorised users

Burton DR (2002) Antibodies, viruses and vaccines. Nat Rev Immunol 2:706–713. doi:10.1038/nri891 CrossRefPubMed

Friguet B, Chaffotte AF, Djavadi-Ohaniance L, Goldberg ME (1985) Measurements of the true affinity constant in solution of antigen-antibody complexes by enzyme-linked immunosorbent assay. J Immunol Methods 77:305–319. doi:10.1016/0022-1759(85)90044-4 CrossRefPubMed

El Bakkouri K, Descamps F, De Filette M et al (2011) Universal vaccine based on ectodomain of matrix protein 2 of influenza A: Fc receptors and alveolar macrophages mediate protection. J Immunol 186:1022–1031. doi:10.4049/jimmunol.0902147 CrossRefPubMed

Laver WG, Air GM, Webster RG, Smith-Gill SJ (1990) Epitopes on protein antigens: misconceptions and realities. Cell 61:553–556CrossRefPubMed

Jegerlehner A, Schmitz N, Storni T, Bachmann MF (2004) Influenza A vaccine based on the extracellular domain of M2: weak protection mediated via antibody-dependent NK cell activity. J Immunol 172:5598–5605CrossRefPubMed

Carragher DM, Kaminski DA, Moquin A et al (2008) A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 181:4168–4176. doi:10.4049/jimmunol.181.6.4168 CrossRefPubMedPubMedCentral

Ackerman ME, Alter G (2013) Opportunities to exploit non-neutralizing HIV-specific antibody activity. Curr HIV Res 11:365–377CrossRefPubMedPubMedCentral

van Zanten J, Harmsen MC, van der Giessen M et al (1995) Humoral immune response against human cytomegalovirus (HCMV)-specific proteins after HCMV infection in lung transplantation as detected with recombinant and naturally occurring proteins. Clin Diagn Lab Immunol 2:214–218PubMedPubMedCentral

Nimmerjahn F, Ravetch JV (2010) Antibody-mediated modulation of immune responses. Immunol Rev 236:265–275. doi:10.1111/j.1600-065X.2010.00910.x CrossRefPubMed

10.

Farrell HE, Shellam GR (1991) Protection against murine cytomegalovirus infection by passive transfer of neutralizing and non-neutralizing monoclonal antibodies. J Gen Virol 72(Pt 1):149–156CrossRef

11.

Klenovsek K, Weisel F, Schneider A et al (2007) Protection from CMV infection in immunodeficient hosts by adoptive transfer of memory B cells. Blood 110:3472–3479. doi:10.1182/blood-2007-06-095414 CrossRefPubMed

12.

Richter K, Oxenius A (2013) Non-neutralizing antibodies protect from chronic LCMV infection independently of activating FcγR or complement. Eur J Immunol 43:2349–2360. doi:10.1002/eji.201343566 CrossRefPubMed

13.

Straub T, Schweier O, Bruns M et al (2013) Nucleoprotein-specific nonneutralizing antibodies speed up LCMV elimination independently of complement and FcγR. Eur J Immunol 43:2338–2348. doi:10.1002/eji.201343565 CrossRefPubMed

14.

Partidos CD, Ripley J, Delmas A et al (1997) Fine specificity of the antibody response to a synthetic peptide from the fusion protein and protection against measles virus-induced encephalitis in a mouse model. J Gen Virol 78(Pt 12):3227–3232CrossRefPubMed

15.

Wright DE, Colaco S, Colaco C, Stevenson PG (2009) Antibody limits in vivo murid herpesvirus-4 replication by IgG Fc receptor-dependent functions. J Gen Virol 90:2592–2603. doi:10.1099/vir.0.014266-0 CrossRefPubMedPubMedCentral

16.

Bournazos S, Klein F, Pietzsch J et al (2014) Broadly neutralizing anti-HIV-1 antibodies require Fc effector functions for in vivo activity. Cell 158:1243–1253. doi:10.1016/j.cell.2014.08.023 CrossRefPubMedPubMedCentral

17.

DiLillo DJ, Tan GS, Palese P, Ravetch JV (2014) Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo. Nat Med 20:143–151. doi:10.1038/nm.3443 CrossRefPubMedPubMedCentral

18.

Jegaskanda S, Job ER, Kramski M et al (2013) Cross-reactive influenza-specific antibody-dependent cellular cytotoxicity antibodies in the absence of neutralizing antibodies. J Immunol 190:1837–1848. doi:10.4049/jimmunol.1201574 CrossRefPubMed

19.

Bournazos S, DiLillo DJ, Ravetch JV (2015) The role of Fc-FcγR interactions in IgG-mediated microbial neutralization. J Exp Med 212:1361–1369. doi:10.1084/jem.20151267 CrossRefPubMedPubMedCentral

20.

Holl V, Peressin M, Moog C (2009) Antibody-mediated Fcγ receptor-based mechanisms of HIV inhibition: recent findings and new vaccination strategies. Viruses 1:1265–1294. doi:10.3390/v1031265 CrossRefPubMedPubMedCentral

21.

Ravetch JV, Bolland S (2001) IgG Fc receptors. Annu Rev Immunol 19:275–290. doi:10.1146/annurev.immunol.19.1.275 CrossRefPubMed

22.

Bruhns P (2012) Properties of mouse and human IgG receptors and their contribution to disease models. Blood 119:5640–5649. doi:10.1182/blood-2012-01-380121 CrossRefPubMed

23.

Bruhns P, Iannascoli B, England P et al (2009) Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113:3716–3725. doi:10.1182/blood-2008-09-179754 CrossRefPubMed

24.

Nimmerjahn F, Ravetch JV (2006) Fcgamma receptors: old friends and new family members. Immunity 24:19–28. doi:10.1016/j.immuni.2005.11.010 CrossRefPubMed

25.

Nimmerjahn F, Ravetch JV (2007) Fc-receptors as regulators of immunity. Adv Immunol 96:179–204. doi:10.1016/S0065-2776(07)96005-8 CrossRefPubMed

26.

Baum LL, Cassutt KJ, Knigge K et al (1996) HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 157:2168–2173PubMed

27.

Chu C-F, Meador MG, Young CG et al (2008) Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms. J Reprod Immunol 78:58–67. doi:10.1016/j.jri.2007.08.004 CrossRefPubMed

28.

Huber VC, Lynch JM, Bucher DJ et al (2001) Fc receptor-mediated phagocytosis makes a significant contribution to clearance of influenza virus infections. J Immunol 166:7381–7388CrossRefPubMed

29.

Lambotte O, Ferrari G, Moog C et al (2009) Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23:897–906. doi:10.1097/QAD.0b013e328329f97d CrossRefPubMedPubMedCentral

30.

McCullough KC, Parkinson D, Crowther JR (1988) Opsonization-enhanced phagocytosis of foot-and-mouth disease virus. Immunology 65:187–191PubMedPubMedCentral

31.

Hessell AJ, Hangartner L, Hunter M et al (2007) Fc receptor but not complement binding is important in antibody protection against HIV. Nature 449:101–104. doi:10.1038/nature06106 CrossRefPubMed

32.

Bonsignori M, Pollara J, Moody MA et al (2012) Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J Virol 86:11521–11532. doi:10.1128/JVI.01023-12 CrossRefPubMedPubMedCentral

33.

Veillette M, Coutu M, Richard J et al (2015) The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibody-dependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals. J Virol 89:545–551. doi:10.1128/JVI.02868-14 CrossRefPubMed

34.

Lewis GK (2014) Role of Fc-mediated antibody function in protective immunity against HIV-1. Immunology 142:46–57. doi:10.1111/imm.12232 CrossRefPubMedPubMedCentral

35.

Corrales-Aguilar E, Trilling M, Reinhard H et al (2013) A novel assay for detecting virus-specific antibodies triggering activation of Fcγ receptors. J Immunol Methods 387:21–35. doi:10.1016/j.jim.2012.09.006 CrossRefPubMed

36.

Griffin DE (2001) Measles virus. In: Knipe D, Howley P (eds) Fields virol. Lippincott, Wlliams & Wilkins, Philadelphia, pp 1401–1441

37.

Cohen BJ, Parry RP, Doblas D et al (2006) Measles immunity testing: comparison of two measles IgG ELISAs with plaque reduction neutralisation assay. J Virol Methods 131:209–212. doi:10.1016/j.jviromet.2005.08.001 CrossRefPubMed

38.

Holzmann H, Hengel H, Tenbusch M, Doerr HW (2016) Eradication of measles: remaining challenges. Med Microbiol Immunol. doi:10.1007/s00430-016-0451-4 PubMedPubMedCentral

39.

Plotkin S (2015) The history of vaccination against cytomegalovirus. Med Microbiol Immunol 204:247–254. doi:10.1007/s00430-015-0388-z CrossRefPubMed

40.

Plotkin SA, Gilbert PB (2012) Nomenclature for immune correlates of protection after vaccination. Clin Infect Dis 54:1615–1617. doi:10.1093/cid/cis238 CrossRefPubMedPubMedCentral

41.

Hengel H, Esslinger C, Pool J et al (1995) Cytokines restore MHC class I complex formation and control antigen presentation in human cytomegalovirus-infected cells. J Gen Virol 76(Pt 12):2987–2997CrossRefPubMed

42.

Rozenblatt S, Eizenberg O, Ben-Levy R et al (1985) Sequence homology within the morbilliviruses. J Virol 53:684–690PubMedPubMedCentral

43.

Hoetzenecker K, Hacker S, Hoetzenecker W et al (2007) Cytomegalovirus hyperimmunoglobulin: mechanisms in allo-immune response in vitro. Eur J Clin Invest 37:978–986. doi:10.1111/j.1365-2362.2007.01881.x CrossRefPubMed

44.

Nigro G, Adler SP, La Torre R, Best AM (2005) Passive immunization during pregnancy for congenital cytomegalovirus infection. N Engl J Med 353:1350–1362. doi:10.1056/NEJMoa043337 CrossRefPubMed

45.

Snydman DR, Werner BG, Heinze-Lacey B et al (1987) Use of cytomegalovirus immune globulin to prevent cytomegalovirus disease in renal-transplant recipients. N Engl J Med 317:1049–1054. doi:10.1056/NEJM198710223171703 CrossRefPubMed

46.

Tischer A, Gassner M, Richard J-L et al (2007) Vaccinated students with negative enzyme immunoassay results show positive measles virus-specific antibody levels by immunofluorescence and plaque neutralisation tests. J Clin Virol 38:204–209. doi:10.1016/j.jcv.2006.12.017 CrossRefPubMed

47.

Bringolf-Isler B, Grize L, Mäder U et al (2009) Assessment of intensity, prevalence and duration of everyday activities in Swiss school children: a cross-sectional analysis of accelerometer and diary data. Int J Behav Nutr Phys Act 6:50. doi:10.1186/1479-5868-6-50 CrossRefPubMedPubMedCentral

48.

Finsterbusch T, Wolbert A, Deitemeier I et al (2009) Measles viruses of genotype H1 evade recognition by vaccine-induced neutralizing antibodies targeting the linear haemagglutinin noose epitope. J Gen Virol 90:2739–2745. doi:10.1099/vir.0.013524-0 CrossRefPubMed

49.

Gonczol E, Furlini G, Ianacone J, Plotkin SA (1986) A rapid microneutralization assay for cytomegalovirus. J Virol Methods 14:37–41CrossRefPubMed

50.

Santibanez S, Niewiesk S, Heider A et al (2005) Probing neutralizing-antibody responses against emerging measles viruses (MVs): immune selection of MV by H protein-specific antibodies? J Gen Virol 86:365–374. doi:10.1099/vir.0.80467-0 CrossRefPubMed

51.

Christenson B, Böttiger M (1994) Measles antibody: comparison of long-term vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine 12:129–133CrossRefPubMed

52.

Santibanez S, Tischer A, Heider A et al (2002) Rapid replacement of endemic measles virus genotypes. J Gen Virol 83:2699–2708CrossRefPubMed

53.

Albrecht P, Herrmann K, Burns GR (1981) Role of virus strain in conventional and enhanced measles plaque neutralization test. J Virol Methods 3:251–260CrossRefPubMed

54.

Ratnam S, Gadag V, West R et al (1995) Comparison of commercial enzyme immunoassay kits with plaque reduction neutralization test for detection of measles virus antibody. J Clin Microbiol 33:811–815PubMedPubMedCentral

55.

Vanarsdall AL, Johnson DC (2012) Human cytomegalovirus entry into cells. Curr Opin Virol 2:37–42. doi:10.1016/j.coviro.2012.01.001 CrossRefPubMed

56.

Varnum SM, Streblow DN, Monroe ME et al (2004) Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV proteome. J Virol 78:10960–10966. doi:10.1128/JVI.78.20.10960-10966.2004 CrossRefPubMedPubMedCentral

57.

Weekes MP, Tomasec P, Huttlin EL et al (2014) Quantitative temporal viromics: an approach to investigate host-pathogen interaction. Cell 157:1460–1472. doi:10.1016/j.cell.2014.04.028 CrossRefPubMedPubMedCentral

58.

Stern-Ginossar N, Weisburd B, Michalski A et al (2012) Decoding human cytomegalovirus. Science 338:1088–1093. doi:10.1126/science.1227919 CrossRefPubMed

59.

Genini E, Percivalle E, Sarasini A et al (2011) Serum antibody response to the gH/gL/pUL128-131 five-protein complex of human cytomegalovirus (HCMV) in primary and reactivated HCMV infections. J Clin Virol 52:113–118. doi:10.1016/j.jcv.2011.06.018 CrossRefPubMed

60.

Haralambieva IH, Simon WL, Kennedy RB et al (2015) Profiling of measles-specific humoral immunity in individuals following two doses of MMR vaccine using proteome microarrays. Viruses 7:1113–1133. doi:10.3390/v7031113 CrossRefPubMedPubMedCentral

61.

de Swart RL, Yüksel S, Osterhaus ADME (2005) Relative contributions of measles virus hemagglutinin- and fusion protein-specific serum antibodies to virus neutralization. J Virol 79:11547–11551. doi:10.1128/JVI.79.17.11547-11551.2005 CrossRefPubMedPubMedCentral

62.

Roche S, Rey FA, Gaudin Y, Bressanelli S (2007) Structure of the prefusion form of the vesicular stomatitis virus glycoprotein G. Science 315:843–848. doi:10.1126/science.1135710 CrossRefPubMed

63.

Nicasio M, Sautto G, Clementi N et al (2012) Neutralization interfering antibodies: a “Novel” example of humoral immune dysfunction facilitating viral escape? Viruses 4:1731–1752. doi:10.3390/v4091731 CrossRefPubMedPubMedCentral

64.

Oda M, Kozono H, Morii H, Azuma T (2003) Evidence of allosteric conformational changes in the antibody constant region upon antigen binding. Int Immunol 15:417–426. doi:10.1093/intimm/dxg036 CrossRefPubMed

65.

Janda A, Bowen A, Greenspan NS, Casadevall A (2016) Ig constant region effects on variable region structure and function. Front Microbiol. doi:10.3389/fmicb.2016.00022 PubMedPubMedCentral

66.

Cohen BJ, Audet S, Andrews N, Beeler J (2007) Plaque reduction neutralization test for measles antibodies: description of a standardised laboratory method for use in immunogenicity studies of aerosol vaccination. Vaccine 26:59–66. doi:10.1016/j.vaccine.2007.10.046 CrossRefPubMed

67.

Kim D, Huey D, Oglesbee M, Niewiesk S (2011) Insights into the regulatory mechanism controlling the inhibition of vaccine-induced seroconversion by maternal antibodies. Blood 117:6143–6151. doi:10.1182/blood-2010-11-320317 CrossRefPubMedPubMedCentral

68.

Sprague ER, Reinhard H, Cheung EJ et al (2008) The human cytomegalovirus Fc receptor gp68 binds the Fc CH2-CH3 interface of immunoglobulin G. J Virol 82:3490–3499. doi:10.1128/JVI.01476-07 CrossRefPubMedPubMedCentral

69.

Atalay R, Zimmermann A, Wagner M et al (2002) Identification and expression of human cytomegalovirus transcription units coding for two distinct Fcgamma receptor homologs. J Virol 76:8596–8608CrossRefPubMedPubMedCentral

70.

Corrales-Aguilar E, Trilling M, Hunold K et al (2014) Human cytomegalovirus Fcγ binding proteins gp34 and gp68 antagonize Fcγ receptors I, II and III. PLoS Pathog 10:e1004131. doi:10.1371/journal.ppat.1004131 CrossRefPubMedPubMedCentral

71.

Corrales-Aguilar E, Hoffmann K, Hengel H (2014) CMV-encoded Fcγ receptors: modulators at the interface of innate and adaptive immunity. Semin Immunopathol 36:627–640. doi:10.1007/s00281-014-0448-2 CrossRefPubMed

72.

Groothuis JR, Simoes EA, Levin MJ et al (1993) Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. The Respiratory Syncytial Virus Immune Globulin Study Group. N Engl J Med 329:1524–1530. doi:10.1056/NEJM199311183292102 CrossRefPubMed

73.

Veazey RS, Shattock RJ, Pope M et al (2003) Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 9:343–346. doi:10.1038/nm833 CrossRefPubMed

74.

Ludwig B, Kraus FB, Kipp M et al (2006) Cytomegalovirus-specific CD4 T-cell and glycoprotein B specific antibody response in recipients of allogenic stem cell transplantation. J Clin Virol 35:160–166. doi:10.1016/j.jcv.2005.06.004 CrossRefPubMed

75.

Muñoz I, Gutiérrez A, Gimeno C et al (2001) Lack of association between the kinetics of human cytomegalovirus (HCMV) glycoprotein B (gB)-specific and neutralizing serum antibodies and development or recovery from HCMV active infection in patients undergoing allogeneic stem cell transplant. J Med Virol 65:77–84CrossRefPubMed

76.

Ward RL, Bernstein DI (1995) Lack of correlation between serum rotavirus antibody titers and protection following vaccination with reassortant RRV vaccines. US Rotavirus Vaccine Efficacy Group. Vaccine 13:1226–1232CrossRefPubMed

77.

Petro C, González PA, Cheshenko N et al (2015) Herpes simplex type 2 virus deleted in glycoprotein D protects against vaginal, skin and neural disease. Elife. doi:10.7554/eLife.06054 PubMedPubMedCentral

78.

Clynes RA, Towers TL, Presta LG, Ravetch JV (2000) Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat Med 6:443–446. doi:10.1038/74704 CrossRefPubMed

79.

Nimmerjahn F, Ravetch JV (2005) Divergent immunoglobulin g subclass activity through selective Fc receptor binding. Science 310:1510–1512. doi:10.1126/science.1118948 CrossRefPubMed

80.

Lowe DB, Shearer MH, Jumper CA et al (2007) Fc gamma receptors play a dominant role in protective tumor immunity against a virus-encoded tumor-specific antigen in a murine model of experimental pulmonary metastases. J Virol 81:1313–1318. doi:10.1128/JVI.01943-06 CrossRefPubMed

81.

Kaneko Y, Nimmerjahn F, Ravetch JV (2006) Anti-inflammatory activity of immunoglobulin G resulting from Fc sialylation. Science 313:670–673. doi:10.1126/science.1129594 CrossRefPubMed

82.

Park-Min K-H, Serbina NV, Yang W et al (2007) FcgammaRIII-dependent inhibition of interferon-gamma responses mediates suppressive effects of intravenous immune globulin. Immunity 26:67–78. doi:10.1016/j.immuni.2006.11.010 CrossRefPubMed

Title: Highly individual patterns of virus-immune IgG effector responses in humans
Authors: Eugenia Corrales-Aguilar
Mirko Trilling
Henrike Reinhard
Valeria Falcone
Albert Zimmermann
Ortwin Adams
Sabine Santibanez
Hartmut Hengel
Publication date: 01-10-2016
Publisher: Springer Berlin Heidelberg
Published in: Medical Microbiology and Immunology / Issue 5/2016
Print ISSN: 0300-8584
Electronic ISSN: 1432-1831
DOI: https://doi.org/10.1007/s00430-016-0457-y

ACC 2024 Congress Coverage

Heart Failure Video

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Highly individual patterns of virus-immune IgG effector responses in humans

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2016

Colonization of CF patients’ upper airways with S. aureus contributes more decisively to upper airway inflammation than P. aeruginosa

A versatile qPCR assay to quantify trypanosomatidic infections of host cells and tissues

Analysis of an echovirus 18 outbreak in Thuringia, Germany: insights into the molecular epidemiology and evolution of several enterovirus species B members

A new report of Nocardiopsis valliformis strain OT1 from alkaline Lonar crater of India and its use in synthesis of silver nanoparticles with special reference to evaluation of antibacterial activity and cytotoxicity

Hand, foot and mouth disease (HFMD): emerging epidemiology and the need for a vaccine strategy

NK cells contribute to persistent airway inflammation and AHR during the later stage of RSV infection in mice

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page